USPTO serial 88581009
ENLIGHTEN HEALTH
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- ANKRAH, NAAKWAMA S
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with ENLIGHTEN HEALTH?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
William M. Bryner
William M. Bryner Kilpatrick Townsend & Stockton LLP1001 West Fourth StreetWinston-Salem, NC 27101UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical products, namely, DNA sequences for use in genotyping, biopolymer profiling, detecting diseases, determining the progression of diseases, and determining drug responses for clinical, medical or medical lab use | ACTIVE | — |
| 042 | Diagnostic and analytical testing services for others, namely, performing tests on biological, environmental, and forensic specimens; providing an interactive web site featuring technology that enables users to access resources in the field of clinical, diagnostic and analytical testing; scientific research consulting in the field of pharmaceutical drug development and testing services; health care laboratories in the nature of medical laboratories; medical laboratories; scientific, technological, biochemical, pharmaceutical, biopharmaceutical, medical and biotechnological research, design and development services in the field of clinical, diagnostic and analytical testing; chemical research; biological research; medical and scientific research, namely, conducting clinical and non-clinical trials for others; medical and scientific research services, namely, conducting pharmaceutical and medical device trials for others; medical and scientific research, namely, organizing, monitoring, managing and supporting clinical trials for others; animal testing services for laboratory and research purposes; medical and scientific laboratory services; rental of laboratory apparatus and instruments for scientific research use; data automation and collection services using proprietary software to evaluate, calibrate, analyze, report and collect clinical and non-clinical data; design and development of clinical and non-clinical trials for others in the field of gene therapy, pharmaceuticals and medical devices; genetic profiling services; research and development in the field of clinical pharmacology services; lead candidate drug optimization services, namely, scientific research in the field of identifying compounds for drug development; clinical and non-clinical pharmaceutical drug development support services; providing an interactive web site featuring technology that enables users to access advisory groups for development of pharmaceutical products and medical devices; scientific research and development in the field of biomarker analysis; genomics and proteomic services in the nature of genome amplification, structural and functional analysis of genomes, clinical research in the field of proteomics; drug formulation research services; chemistry services, namely, laboratory research and analysis in the field of chemistry; custom assay development and validation; conducting scientific and laboratory research in the fields of computational biology and bioinformatics in relation to the data mining, quality assessment, data and network analysis and interpretation of biological data; services relating to temporary electronic storage, aggregation, capture and analysis of clinical and non-clinical study information; medical and scientific research services, namely, creating and maintaining databases for others in the fields of scientific, technological, biochemical, pharmaceutical, biopharmaceutical, medical and biotechnological research, testing and development services; medical and scientific research services, namely, tracking, monitoring, analyzing and generating reports, information and statistics for clinical and non-clinical pharmaceutical and medical device development studies, clinical trials, patient reimbursement and insurance coverage for pharmaceuticals and medical devices; design and development of animal and biological research tools for non-clinical pharmaceutical and medical device development studies; providing clinical and non-clinical trial and research information online from a computer database or the internet; scientific consultancy services in relation to biomarker selection; scientific and technological consultancy services in relation to animal and biological research model selection; providing a web-based portal featuring on-line non-downloadable software in the field of medical information management services for use in collecting, organizing, and reporting medical information, medical records, and diagnostic testing records; application service provider, namely, hosting, managing, developing, analyzing, and maintaining applications, software, and web sites in the fields of medical testing, testing for forensic purposes, testing for quality control purposes, genetic testing, clinical and analytical testing, disease, medical care, healthcare, pharmaceuticals, medical devices, biochemicals, and biotechnology; providing temporary use of online non-downloadable software for storing, retrieving, accessing, displaying, managing, analyzing, and reviewing information and data in the fields of medical testing, testing for forensic purposes, testing for quality control purposes, genetic testing, clinical and analytical testing, disease, medical care, healthcare, pharmaceuticals, medical devices, biochemicals, and biotechnology; medical and scientific research, namely, designing, organizing, conducting, monitoring, and managing clinical and non-clinical trials and studies on pharmaceuticals and medical devices for others; scientific consulting services for others in the field of clinical and non-clinical trials and studies on pharmaceuticals and medical devices; medical and scientific research services, namely, collection, calibration, analysis and reporting of medical and scientific research data in connection with clinical and non-clinical trials and studies on pharmaceuticals and medical devices; medical and scientific research services, namely, operating and maintaining a biorepository for medical and scientific research purposes; scientific research and analysis in the fields of bioinformatics, biomarkers, genomics, proteomics, genotyping, and genetic profiling; custom design and development of chemical reagents and biochemical assays; testing of laboratory animals for scientific research purposes; design and development of software for use in conducting animal and biological research in non-clinical pharmaceutical and medical device and development studies; providing online computer databases in the fields of medical research and development of pharmaceuticals, medical devices, biotechnology, and biochemical; providing a website featuring technology enabling users to remotely track, monitor, analyze, and generate reports with information and statistics from clinical and non-clinical trials and studies on pharmaceuticals and medical devices; food safety testing and consultation related thereto; scientific research and analysis in the fields of food safety, food packaging, and nutritional chemistry; scientific research and analysis in the field of pharmacology; advisory services in the field of pharmaceutical drug development, namely, providing advice in selecting animal and biological research models for use in testing drugs; advisory services in the field of pharmaceutical drug development, namely, providing advice in selecting biomarkers for use in testing drugs; providing scientific information in the fields of biochemistry, pharmaceuticals and clinical trials; providing online non-downloadable software for tracking, monitoring, analyzing, generating and reporting information and statistics about patient reimbursement and insurance coverage for pharmaceuticals and medical devices; application service provider (ASP) featuring software for use in database and record management in the fields of medical testing, testing for forensic purposes, testing for quality control purposes, genetic testing, clinical and analytical testing, disease, medical care, healthcare, pharmaceuticals, medical devices, biochemicals, and biotechnology; analytical testing, namely, laboratory services for analytical testing of medical samples | ACTIVE | — |
| 044 | Health care; medical testing and diagnosis; providing health information; medical evaluation services, namely, evaluating programs for disease detection, management and treatment protocols; medical analysis services for the diagnosis and treatment of persons; medical services in the fields of pathology, pharmacology, and immunology; medical and psychological counseling; providing medical information and advice in the fields of pathology, pharmacology, and immunology; health care services, namely, providing a database in the field of clinical and non-clinical trials and studies on pharmaceuticals and medical device all for treatment and diagnostic purposes; anatomic and clinical pathology services; pharmacology consultancy services; patient and clinical trial volunteer consultancy services; health counseling; medical services, namely, immunology services; medical testing of urine, blood, hair follicles and breath for forensic and quality control purposes; consulting services in the fields of medical testing, testing for forensic purposes, testing for quality control purposes, genetic testing, clinical disease, healthcare, patient management and outcomes, and/or healthcare management and operations; providing an internet website for medical professionals and medical patients featuring medical information from remote locations via devices that feed information to the website that is processed, exchanged, and accessed in real-time by users in the fields of medical testing, testing for forensic purposes, testing for quality control purposes, genetic testing, clinical, disease, healthcare, patient management and outcomes, and/or healthcare management and operations; pharmaceutical drug testing services; providing medical information in the fields of biochemistry, pharmaceuticals and clinical trials. medical services; clinical testing for diganostic and treatment purposes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Laboratory Corporation of America Holdings
- Other trademarks owned by Laboratory Corporation of America Holdings
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named ENLIGHTEN HEALTH
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 3, 2023 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jan 2, 2023 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Dec 3, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 1, 2021 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Dec 1, 2021 | EXT2 | SOU EXTENSION 2 FILED | — |
| Dec 1, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 1, 2021 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Dec 1, 2021 | EXT1 | SOU EXTENSION 1 FILED | — |
| Dec 1, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 1, 2021 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Apr 6, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 6, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 17, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 2, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 2, 2021 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Mar 2, 2021 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Mar 2, 2021 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Mar 2, 2021 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Feb 17, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 17, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 17, 2021 | ALIE | ASSIGNED TO LIE | — |
| Nov 13, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 14, 2020 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 14, 2020 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 14, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 30, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 30, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 30, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 5, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 5, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 5, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 28, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 31, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 19, 2019 | NWAP | NEW APPLICATION ENTERED | — |